EXAM - WALDEN UNIVERSITY - 2026/2027 ACADEMIC YEAR
- VERIFIED QUESTIONS AND ANSWERS
160 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NRNP 6541 ADVANCED PRACTICE NURSING FINAL ACTUAL EXAM - WALDEN UNIVERSITY - 2026/2027
ACADEMIC YEAR - VERIFIED QUESTIONS AND ANSWERS. It contains 160 carefully selected questions that
reflect the most current exam content and testing strategies. Each question is accompanied by a correct answer
and a detailed rationale that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 160 Questions
Foundations - Application - NRNP 6541 Advanced Nursing Actual Walden University 2026/2027 Academic
YEAR AND Advanced Nursing Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
NRNP 6541 Advanced 1-27 Acute, Appropriate, Chronic, Disease, Initial
Nursing Actual Walden
University 2026/2027
Academic YEAR AND
Advanced Nursing Graduate
Acute 28-54 Appropriate, Chronic, Management, Failure, Rather
Chronic 55-81 Describes, Appropriate, Primary, Heart, Intervention
Disease 82-108 Appropriate, Acute, Suspected, Syndrome, Metformin
Kidney 109-135 Chronic, Disease, Therapy, Diabetes, Stage
Diabetes 136-160 Appropriate, Disease, Strategy, Management, Chronic Kidney
TOTAL 160 All questions include answers and detailed rationales
,Section A - NRNP 6541 Advanced Nursing Actual Walden
University 2026/2027 Academic YEAR AND Advanced
Nursing Graduate
Q1.
A patient with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min) is being
started on an SGLT2 inhibitor. Which statement best reflects the current evidence-based
recommendation?
A. SGLT2 inhibitors are contraindicated at B. SGLT2 inhibitors can be initiated but may
this eGFR and should be avoided. lose glucose-lowering efficacy at this eGFR.
C. SGLT2 inhibitors are preferred agents D. SGLT2 inhibitors require dose adjustment
regardless of eGFR because of based solely on eGFR.
cardiovascular benefits.
Correct: B - SGLT2 inhibitors can be initiated but may lose glucose-lowering efficacy at
this eGFR.
Rationale:SGLT2 inhibitors are not recommended for glycemic control when eGFR is below
30, but can be continued for cardiovascular/renal benefits. Their glucose-lowering efficacy
diminishes with declining renal function. They are not contraindicated, but the primary benefit
shifts from glycemic control to organ protection.
Q2.
In a patient with suspected acute coronary syndrome, which ECG finding is most specific
for acute ischemia and warrants immediate reperfusion therapy?
A. ST-segment depression in leads V1-V3 B. Hyperacute T waves in multiple leads
C. New left bundle branch block with D. ST-segment elevation in two contiguous
hemodynamic instability leads
Correct: D - ST-segment elevation in two contiguous leads
Rationale:ST-segment elevation in two anatomically contiguous leads is the classic STEMI
criterion, indicating transmural ischemia and requiring immediate reperfusion. Hyperacute T
waves may precede STEMI but are not diagnostic alone. New LBBB with instability is also an
indication, but ST elevation is the most specific for acute coronary occlusion.
Q3.
A 45-year-old patient presents with fatigue, weight gain, and cold intolerance. Labs show
elevated TSH and low free T4. Which additional finding would most strongly support a
diagnosis of Hashimoto's thyroiditis over other causes of primary hypothyroidism?
Page 3
, Section A - NRNP 6541 Advanced Nursing Actual Walden University 2026/2027 Academic YEAR AND Advanced Nursing Graduate
A. Elevated thyroglobulin antibodies B. Low thyroid peroxidase antibodies
C. Positive thyroid-stimulating D. Diffuse goiter on ultrasound
immunoglobulin
Correct: A - Elevated thyroglobulin antibodies
Rationale:Elevated thyroglobulin antibodies, along with TPO antibodies, are characteristic of
Hashimoto's thyroiditis, an autoimmune cause of primary hypothyroidism. Low TPO
antibodies would be atypical. Thyroid-stimulating immunoglobulin is associated with Graves'
disease. Diffuse goiter is nonspecific and can occur in other forms of hypothyroidism.
Q4.
According to the latest hypertension guidelines, which blood pressure threshold defines
stage 1 hypertension in adults, and what is the recommended initial treatment for most
patients at this stage?
A. 130-139/80-89 mm Hg; lifestyle B. 130-139/80-89 mm Hg; lifestyle
modification alone for all patients modification plus antihypertensive
medication if cardiovascular risk is high
C. 140-159/90-99 mm Hg; lifestyle D. 120-129/<80 mm Hg; lifestyle
modification alone for low-risk patients modification plus antihypertensive
medication
Correct: B - 130-139/80-89 mm Hg; lifestyle modification plus antihypertensive medication
if cardiovascular risk is high
Rationale:According to ACC/AHA guidelines, stage 1 hypertension is defined as
130-139/80-89 mm Hg. For most patients, lifestyle modification is the first step, but if the
patient has high cardiovascular risk (e.g., ASCVD risk 10%), pharmacotherapy is indicated.
This approach reflects the latest evidence-based recommendations.
Q5.
A patient with generalized anxiety disorder has been on sertraline for 6 weeks with partial
response. Which of the following is the most appropriate next step, considering current
evidence-based treatment algorithms?
A. Switch to a different SSRI immediately B. Increase the sertraline dose to the
maximum tolerated dose
C. Add a benzodiazepine for long-term D. Augment with an atypical antipsychotic
adjunctive therapy as first-line
Correct: B - Increase the sertraline dose to the maximum tolerated dose
Page 4